Darwin Global Management »

Moonlake Immunot shares owned by Darwin Global Management

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $63M 1.0M 60.39

More positions owned by Darwin Global Management

Ambrx Biopharma
Tg Therapeutics (TGTX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Vaxcyte (PCVX)
Springworks Therapeutics (SWTX)
Nuvalent Inc-a (NUVL)

View all positions for Darwin Global Management

Top funds holding Moonlake Immunot

BVF
Cormorant Asset Management
venBio Select Advisor
T. Rowe Price Associates
Citadel Advisors
Federated Investors
Darwin Global Management
Holocene Advisors
Alliancebernstein
Fred Alger Management
Westfield Capital Management Company
Balyasny Asset Management
TimesSquare Capital Management
Caption Management
5AM Venture Management

View all funds holding Moonlake Immunot